Evidence map›Paper›PMID 39309724›Full record

ArticleEClinicalMedicine2024

Upfront or delayed surgery in resectable hepatoblastoma: analysis from the children's hepatic tumors international collaboration database.

Eiso Hiyama, Tomoro Hishiki, Kenichi Yoshimura, Mark Krailo, Rudolf Maibach, Beate Haeberle, Arun Rangaswami, Dolores Lopez-Terrada, Marcio H Malogolowkin, Marc Ansari and 13 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Hepatoblastoma.Nature reviews. Disease primers · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Eiso HiyamaNatural Science for Basic Research and Development, Department of Pediatric Surgery, Hiroshima University Hospital, Hiroshima University, Hiroshima, Japan.
Tomoro HishikiDepartment of Pediatric Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Kenichi YoshimuraDepartment of Biostatistics and Health Data Science, Nagoya City University, Japan.
Mark KrailoDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA, USA.
Rudolf MaibachETOP IBCSG Partners Foundation, Bern, Switzerland.
Beate HaeberleDepartment of Pediatric Surgery, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Germany.
Arun RangaswamiDivision of Pediatric Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA.
Dolores Lopez-TerradaDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
Marcio H MalogolowkinDivision of Pediatric Hematology Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Marc AnsariCansearch Research Platform for Pediatric Oncology and Hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland.
Rita AlaggioPathology Unit, IRCCS Ospedale Pediatrico Bambino Gesu Pediatric Hospital, Roma, Italy.
Allison F O'NeillDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Angela D Trobaugh-LotrarioDepartment of Pediatric Hematology/Oncology, Providence Sacred Heart Children's Hospital, Spokane, WA, USA.
Kenichiro WatanabeDepartment of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.
Irene SchmidDepartment of Pediatric Hematology and Oncology, Dr. von Hauner Children`s Hospital, University Hospital, LMU Munich, Munich, Germany.
Sarangarajan RanganathanDivision of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Yukichi TanakaDepartment of Pathology, Kanagawa Children's Medical Center, Yokohama, Japan.
Takeshi InoueDepartment of Pathology, Osaka City General Hospital, Osaka, Japan.
Jin PiaoDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA, USA.
Jason LinDivision of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Piotr CzaudernaDepartment of Surgery and Urology, for Children and Adolescents, Medical University of Gdansk, Poland.
Rebecka L MeyersDivision of Pediatric Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA.
Daniel C AronsonDepartment of Pediatric Surgery, University Children's Hospital Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In the treatment of resectable hepatoblastoma (HB), it has not been established whether upfront surgery (UF) at diagnosis or neoadjuvant chemotherapy and delayed surgery (DL) is preferred. We compared patients with localized HB who underwent either UF, or DL after neoadjuvant chemotherapy in the Children's Hepatic tumors International Collaboration (CHIC) database of 1605 cases enrolled in eight multicenter hepatoblastoma trials between 1988 and 2010. Methods: Among the 512 resectable HB patients who had PRETEXT (PRETreament EXTent of disease) I or II unruptured tumors at diagnosis without extrahepatic invasion, distant metastases, or massive vascular invasion, 172 underwent UF and 340 underwent DL. The primary outcomes were event-free and overall survivals after start of treatment in these two groups. Survival analysis was performed using the Kaplan-Maier analysis with long-rank tests and multivariable Cox regression models. Findings: Complete resection rates were comparable (93.6% in UF and 89.7% in DL). The total cycles of chemotherapy of DL (median:6) were significantly more than those of UF (median:4) ( Interpretation: The outcomes, surgical resectability, and complications were not significantly different between the UF and DL groups. Eligible patients with a low AFP level (<1000 ng/mL) or older age (≥3 years old) showed better outcomes in the UF group and might be considered for initial resection. Funding: European Network for Cancer Research in Children and Adolescents, funded through the Framework Program 7 of the European Commission; Children's Oncology Group Cure Search grant contributed by the Hepatoblastoma Foundation; Practical Research for Innovative Cancer Control and Project Promoting Clinical Trials for Development of New Drugs and Medical Devices, Japan Agency for Medical Research and Development; Japan Society for the Promotion of Science; and Swiss Cancer Research grant.

Indexed as

Age at diagnosisAlpha-fetoproteinHepatoblastomaOutcomeResectableUp-front surgery

Identifiers

PMID39309724
PMCPMC11414700

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.